Navigation Links
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
Date:8/27/2008

is and the National Cancer Institute (NCI). The study was led by the American College of Surgeons Oncology Group (ACOSOG).

The investigators reported that Gleevec therapy was well tolerated by most patients, with side effects similar to those observed in previous clinical trials with Gleevec. These include nausea, diarrhea and swelling (edema)(3).

About gastrointestinal stromal tumors (GIST)

Gastrointestinal stromal tumors (GIST) belong to a group of cancers known as soft tissue sarcomas. They are the most common sarcomas and can be found most often in the stomach and small intestine. The incidence of GIST is estimated to be 4,500 - 6,000 new cases per year in the US (15-20 cases per million population)(5), of which more than 90% are kit-positive(6). Kit -- also known as CD117 -- is a protein that, when mutated, has been identified as one of the major causes of GIST.

About Gleevec

Gleevec(R) (imatinib mesylate) tablets are indicated for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase. Follow-up is limited to 5 years. Gleevec is also indicated for the treatment of patients with Ph+ CML in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha (IFN-alpha) therapy; adult patients with relapsed or refractory Ph+ acute lymphoblastic leukemia (Ph+ ALL); adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene rearrangements; adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-KIT mutation or with c-KIT mutational status unknown; adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1- PDGFR alpha fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-
'/>"/>

SOURCE Novartis
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
2. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
3. Omaxe Infrastructure & Construction Private Ltd Receives LoI for Construction of Allopathic Medical College and Associated Hospital at Saharanpur, UP With Construction Value of Approx 250 Crores
4. Caliper Life Sciences Receives $1.1 Million Task Order from the EPAs ToxCast(TM) Screening Program
5. Biotest Diagnostics Receives FDA Clearance for Full Line of Traditional Blood Bank Reagents
6. BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC
7. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
8. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
9. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
10. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
11. Medicsight Receives Brazilian State Food and Drug Administration Approval for ColonCAD Software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... culture supplement? InVitria has what scientists have been asking for! ... improves the growth and productivity of CHO cells. Developed for ... animal free, well defined and consistent recombinant CHO supplement. ... ... 16, 2009 -- Scientists working with CHO cells can now ...
(Date:12/16/2009)... its 23rd Annual Technical Conference & Exhibition on March 22-25, 2010 ... impact the separation society and reach out to even more experts ... AFS Annual Technical Conference will be co-located with the 2010 AIChE ... ... December 16, 2009 -- The American Filtration and Separations Society will ...
(Date:12/15/2009)... 15 Repligen Corporation (Nasdaq: RGEN ... $731,000 in research funding to support the ongoing ... the Muscular Dystrophy Association (MDA). This grant ... testing and GMP manufacture of a drug candidate ... MDA not only provides important funding for Repligen,s ...
(Date:12/15/2009)... DIEGO, Dec. 15 Aethlon Medical, Inc. ... Dr. Jeff Schorey and Dr. Wayne Comper ... Exosome Sciences, Inc. (ESI). Both Dr. Schorey and ... field. ESI, a wholly owned subsidiary of Aethlon ... that the Hemopurifier®, a medical device being advanced ...
Breaking Biology Technology:Online Video of InVitria's Zap-CHO Helps Scientists Maximize CHO Cell Culture Performance 2American Filtration and Separations Society to Hold 23nd Annual Technical Conference 2American Filtration and Separations Society to Hold 23nd Annual Technical Conference 3American Filtration and Separations Society to Hold 23nd Annual Technical Conference 4Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program 2Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program 3Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 2Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 3Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 4Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 5
... announced today that the Company will host an investor ... PM Eastern Time to present an,analysis of the data ... IT-R-006) for the treatment of nasolabial folds, or,wrinkles. On ... results from these two studies, which met all primary ...
... benefits of ACTEMRA for rheumatoid,arthritis -, NUTLEY, ... a,total of 15 abstracts involving its investigational rheumatoid ... presentation,at the 2008 American College of Rheumatology (ACR) ... in San Francisco. These,studies evaluate ACTEMRA, a novel ...
... Ventures for Global Health to Work with Industry ... BIO Ventures for Global,Health (BVGH) today announced ... (FDA) release of Draft Guidance for Industry on ... is designed to,encourage industry investment in the development ...
Other Biology Technology:Isolagen to Host Investor Conference Call to Present an Analysis of the Data from Phase III Wrinkle Studies 2ACTEMRA(R) (tocilizumab) Studies to be Featured at American College of Rheumatology Annual Scientific Meeting 2ACTEMRA(R) (tocilizumab) Studies to be Featured at American College of Rheumatology Annual Scientific Meeting 3ACTEMRA(R) (tocilizumab) Studies to be Featured at American College of Rheumatology Annual Scientific Meeting 4FDA Issues Draft Guidance on Priority Review Vouchers 2
(Date:12/16/2009)... DC US Secretary of Energy Steven Chu announced ... for their outstanding contributions in research and development supporting ... six winners named today will receive a gold medal, ... honored at a ceremony in Washington, DC early next ... the national, economic and energy security of the United ...
(Date:12/16/2009)... get psyched up for contests, but when these rituals ... down before and during events, they could be causing ... for the symptoms of an injury, not the injury ... focuses on musculoskeletal health and sports medicine. "They may ... certain level, but pain occurs for a reason. It ...
(Date:12/16/2009)... Medicine researcher will lead the coordinating center for a ... field of stem cell research. Michael L. Terrin, M.D.,C.M.,M.P.H., ... the National Heart, Lung and Blood Institute (NHLBI) to ... which will be called the NHLBI Progenitor Cell Biology ... $30 million grant over seven years. , ...
Breaking Biology News(10 mins):Secretary Chu announces 2009 Ernest Orlando Lawrence Award winners 2NSAIDs: Take 'em early and often when competing? Think again 2University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium 2University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium 3Par Pharmaceutical Reports EPS of 240 71 for Second Quarter 2009 53593 1Par Pharmaceutical Reports EPS of 240 71 for Second Quarter 2009 53593 2Par Pharmaceutical Reports EPS of 240 71 for Second Quarter 2009 53593 3Par Pharmaceutical Reports EPS of 240 71 for Second Quarter 2009 53593 4Par Pharmaceutical Reports EPS of 240 71 for Second Quarter 2009 53593 5Par Pharmaceutical Reports EPS of 240 71 for Second Quarter 2009 53593 6Par Pharmaceutical Reports EPS of 240 71 for Second Quarter 2009 53593 7Par Pharmaceutical Reports EPS of 240 71 for Second Quarter 2009 53593 8Par Pharmaceutical Reports EPS of 240 71 for Second Quarter 2009 53593 9Par Pharmaceutical Reports EPS of 240 71 for Second Quarter 2009 53593 10Par Pharmaceutical Reports EPS of 240 71 for Second Quarter 2009 53593 11Par Pharmaceutical Reports EPS of 240 71 for Second Quarter 2009 53593 12Par Pharmaceutical Reports EPS of 240 71 for Second Quarter 2009 53593 13ETC Biomedical Announces Chamber Sale in India 13344 1ETC Biomedical Announces Chamber Sale in India 13344 2ETC Biomedical Announces Chamber Sale in India 13344 3ETC Biomedical Announces Chamber Sale in India 13344 4OmniComm Systems Acquires EDC Assets of Leading Phase I Clinical Software Vendor Logos Technologies Ltd 13341 1OmniComm Systems Acquires EDC Assets of Leading Phase I Clinical Software Vendor Logos Technologies Ltd 13341 2OmniComm Systems Acquires EDC Assets of Leading Phase I Clinical Software Vendor Logos Technologies Ltd 13341 3
... at Washington University in St. Louis and Arizona State University have ... by making an even rarer form of chlorophyll, chlorophyll d. Chlorophyll ... to the naked eye. , ... with virtually no other plant or bacterium in the world for ...
... of the most important metabolic processes in our bodies, ... intermediates have been produced in multigram quantitieswith one exception, ... University of Leipzig have finally done it. As they ... combination of one biotechnological and one chemical step, starts ...
... with diabetes, cardiac problems, kidney disorders or high blood ... technology. The new "smart" holograms, which can detect ... much simpler, cheaper and more reliable, write Chris Lowe ... hologram is a recording of an optical interference pattern ...
Other Biology News:Bacterium sequenced makes rare form of chlorophyll 2Bacterium sequenced makes rare form of chlorophyll 3Kilogram quantities at last! 2'Smart' holograms help patients help themselves 2